Patients with psoriasis are often affected by comorbidities, which largely influence treatment
decisions. Here we performed conjoint analysis to assess the impact of comorbidities on …

Treatment dissatisfaction and non-adherence are common among patients with psoriasis,
partly due to discordance between individual preferences and recommended treatments …

BACKGROUND: Non-adherence rates are high among patients with psoriasis, partly
because of discordance between recommended treatments and individual preferences …

Background Patients with psoriasis have increased prevalence of coronary risk factors and
limited recent results have suggested that these risk factors are undertreated in patients with …

Concerns have been raised regarding an increased risk of major adverse cardiovascular
events (MACEs)(myocardial infarction, cerebrovascular accident or cardiovascular death) in …

TNF inhibitors have been used in psoriasis (Pso) and psoriatic arthritis (PsA), which were
associated with increased risk of cardiac and cerebrovascular events. However, whether …

This nationwide population-based cohort study aimed to investigate the impact of systemic
anti-inflammatory treatment on the major adverse cardiovascular events (MACE) risk in …

Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVE s; acute …

Abstract Purpose of Review The aim of this review is to summarize the literature on the
effects of biologic treatment for psoriasis on the risk of cardiovascular (CV) disease (CVD) …

Introduction: Patients with psoriasis have an increased incidence and prevalence of
cardiovascular (CV) risk factors, and CV undertreatment in these patients is a well …